KRAS and non-small cell lung carcinoma: KRAS alterations have been observed in about one quarter of NSCLC patients and occur primarily at codon twelve, where the most prevalent change is a glycine-to-cysteine substitution resulting in the KRASG12C gene mutation [5,6,7,8].